Absci Corporation

Contributing Author

Recent Articles by Absci Corporation

Oct-27	Absci to Participate in Upcoming Investor Conferences ABSI GlobeNewswire
Oct-15	Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial ABSI GlobeNewswire
Aug-25	Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg ABSI GlobeNewswire
Aug-20	Absci to Participate in Upcoming Investor Conferences ABSI GlobeNewswire
Aug-12	Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results ABSI GlobeNewswire
Aug-07	Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target ABSI GlobeNewswire
Jul-30	Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025 ABSI GlobeNewswire
Jul-24	Absci Announces Pricing of Public Offering of Common Stock ABSI GlobeNewswire
Jul-24	Absci Announces Proposed Public Offering of Common Stock ABSI GlobeNewswire
Jul-07	Absci Appoints Biopharma Leader Mary Szela to Board of Directors ABSI GlobeNewswire
May-20	Absci to Participate in Upcoming Investor Conferences ABSI GlobeNewswire
May-13	Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results ABSI GlobeNewswire
May-13	Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease ABSI GlobeNewswire